Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting

Wednesday, February 21, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

ROCKVILLE, Md. and HONG KONG, Feb. 21, 2018 /PRNewswire-USNewswire/ -- Ascentage Pharma,

a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate
APG-1252, a novel Bcl-2/Bcl-xL dual inhibitor. The data will be presented by Dajun Yang, M.D., Ph.D., the Company's Chairman & Chief Executive Officer, during the International Association for the Study of Lung Cancer (IASLC) 18th Lung Cancer Targeted Therapies Meeting, held in Santa Monica, CA from February 21-24.

About APG-1252APG-1252 is a highly potent investigational small molecule that selectively binds to and inhibits Bcl-2 and Bcl-xL proteins, both of which play pivotal roles in regulating programmed cell death, or apoptosis. APG-1252 is designed to overcome on-target toxicity of platelets that may occur during Bcl-xL inhibition, while maintaining strong anti-tumor potency. In preclinical studies, APG-1252 achieved complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose schedule, including small cell lung cancer (SCLC), colon cancer, breast cancer and acute lymphoblastic leukemia. APG-1252 also demonstrated strong synergy with chemotherapeutic agents, indicating that it may have broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is being investigated in Phase 1 clinical studies in patients with SCLC or other solid tumors.

About Ascentage PharmaAscentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

Media ContactAmy Bonanno E-mail: abonanno@bmccommunications.comPhone: +1 914 450 0349

Investor ContactChad RubinE-mail: crubin@troutgroup.comPhone: +1 646 378 2947

Cision View original content:http://www.prnewswire.com/news-releases/ascentage-pharma-to-present-at-the-iaslc-18th-lung-cancer-targeted-therapies-meeting-300601762.html

SOURCE Ascentage Pharma



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store